

Acute Ischemic Stroke Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports

DelveInsight's Acute Ischemic Stroke Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LA, UNITED STATES, June 19, 2024 /EINPresswire.com/ --

The Acute Ischemic Stroke market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.

Furthermore, launching various multiple-stage Acute Ischemic Stroke pipeline products will significantly revolutionize the Acute Ischemic Stroke market dynamics.

DelveInsight's "Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Acute Ischemic Stroke, historical and forecasted epidemiology as well as the Acute Ischemic Stroke market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Acute Ischemic Stroke market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Acute Ischemic Stroke Market Forecast](#)

Some of the key facts of the Acute Ischemic Stroke Market Report:

The Acute Ischemic Stroke market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

In 2022, the market size of acute ischemic stroke (AIS) in the US was approximately USD 787.5 million, and it is expected to grow by 2034.

In the EU4 countries and the UK, Germany led with the highest market size, totaling nearly USD 147.5 million in 2022, followed by the UK with approximately USD 77.1 million in the same year. According to DelveInsight's analysis, in 2022, the total number of new cases of acute ischemic stroke (AIS) was approximately 1,608,975 in the 7 Major Markets (7MM). These numbers are expected to rise in the forecast period from 2023 to 2034.



Acute Ischemic Stroke Market

In 2022, the United States reported the highest number of acute ischemic stroke (AIS) cases among the 7 Major Markets (7MM), totaling about 738,420 cases, while the EU4 countries (France, Germany, Italy, Spain) and the UK accounted for approximately 636,693 cases. In 2022, assessments indicated that nearly 368,471 males and 369,948 females in the US were affected by acute ischemic stroke (AIS). These numbers are projected to rise in the forecast period from 2023 to 2034.

In the EU4 countries and the UK, the age group of 75-84 years had the highest number of acute ischemic stroke (AIS) cases, making up approximately 31% of the total cases in 2022. In contrast, the age group of 0-64 years accounted for the fewest cases, totaling 22%.

Key Acute Ischemic Stroke Companies: Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie, and others

Key Acute Ischemic Stroke Therapies: Nerinetide, Invimestrocel (HLCM051), MultiStem, BMS986177, LT-3001, Elezanumab, and others

According to analysts at DelveInsight, in 2022, approximately 368,471 males and 369,948 females in the US were diagnosed with acute ischemic stroke (AIS).

The Acute Ischemic Stroke epidemiology based on gender analyzed that men are at higher risk for Acute Ischemic Stroke than women

Acute Ischemic Stroke Overview

Acute ischemic stroke is a medical condition characterized by a sudden interruption in blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This interruption is usually caused by a blockage in an artery supplying blood to the brain, such as a blood clot or atherosclerotic plaque.

Get a Free sample for the Acute Ischemic Stroke Market Report:

https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Acute Ischemic Stroke Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Ischemic Stroke Epidemiology Segmentation:

The Acute Ischemic Stroke market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Acute Ischemic Stroke

Prevalent Cases of Acute Ischemic Stroke by severity

Gender-specific Prevalence of Acute Ischemic Stroke

Diagnosed Cases of Episodic and Chronic Acute Ischemic Stroke

Download the report to understand which factors are driving Acute Ischemic Stroke epidemiology trends @ [Acute Ischemic Stroke Epidemiological Forecast](#)

Acute Ischemic Stroke Market

The dynamics of the Acute Ischemic Stroke market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

Acute Ischemic Stroke Therapies and Key Companies

Nerinetide: NoNO

Invimestrocel (HLCM051): Athersys/Healios K.K.

BMS986177: Bristol-Myers Squibb

LT-3001: Lumosa Therapeutics

Elezanumab: Abbvie

MultiStem: Athersys/Healios K.K.

Acute Ischemic Stroke Market Strengths

Improved knowledge of stroke pathophysiology, awareness of symptoms, and developments in acute stroke care in the last two decades

The availability of national registries allows the investigation of trends in patient management and clinical development

Various organizations are focusing on research and development for novel therapies

Robust pipeline consisting of candidates with the potential to address the unmet need of AIS patients

Acute Ischemic Stroke Market Barriers

Development of stem cell therapies and newer thrombolytic agents with a shorter half-life, and rapid onset of action, might be safe and effective for AIS patients giving pharma players wide opportunities

The high incidence and increasing awareness would lead to higher revenue in future

No neuroprotective agents have yet been approved to protect brain cells at risk due to acute trauma, allowing pharma giants to explore this area

Scope of the Acute Ischemic Stroke Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Acute Ischemic Stroke Companies: Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie, and others

Key Acute Ischemic Stroke Therapies: Nerinetide, Invimestrocel (HLCM051), MultiStem, BMS986177, LT-3001, Elezanumab, and others

Acute Ischemic Stroke Therapeutic Assessment: Acute Ischemic Stroke current marketed and Acute Ischemic Stroke emerging therapies

Acute Ischemic Stroke Market Dynamics: Acute Ischemic Stroke market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Acute Ischemic Stroke Market Access and Reimbursement

Discover more about therapies set to grab major Acute Ischemic Stroke market share @ [Acute Ischemic Stroke Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Acute Ischemic Stroke Market Report Introduction
2. Executive Summary for Acute Ischemic Stroke
3. SWOT analysis of Acute Ischemic Stroke
4. Acute Ischemic Stroke Patient Share (%) Overview at a Glance
5. Acute Ischemic Stroke Market Overview at a Glance
6. Acute Ischemic Stroke Disease Background and Overview
7. Acute Ischemic Stroke Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Ischemic Stroke
9. Acute Ischemic Stroke Current Treatment and Medical Practices
10. Acute Ischemic Stroke Unmet Needs
11. Acute Ischemic Stroke Emerging Therapies
12. Acute Ischemic Stroke Market Outlook
13. Country-Wise Acute Ischemic Stroke Market Analysis (2020–2034)
14. Acute Ischemic Stroke Market Access and Reimbursement of Therapies
15. Acute Ischemic Stroke Market drivers
16. Acute Ischemic Stroke Market barriers
17. Acute Ischemic Stroke Appendix
18. Acute Ischemic Stroke Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/721328094>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.